Denis Fedorinov

Dr. Denis Fedorinov


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2019 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
KMK. B. Mirzaev
K. B. Mirzaev
DFDenis Fedorinov
Denis Fedorinov
DID. V. Ivashchenko
D. V. Ivashchenko
DSDmitry Sychev
Dmitry Sychev
Aim. To summarize Russian studies using pharmacogenetic testing as applied to cardiology.Material and methods. The authors conducted an online search for articles in December 2018 using the following databases: PubMed, Google Scholar, eLIBRARY. The search was carried out by keywords: "Russia", "Russian", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «CYP2C19», «CYP2D6», «CYP2B1», «CYP2B6», «CYP2Е1», «CYP2C8», «CYP2C9», «CYP3A4», «CYP3A5», «CYP1A1», «CYP1A2», «CYP4F2», «CYP4F1», «ABCB1», «SLCO1B1», «VKORC1», «GGCX», «SULT1A1», «CULT1», «CES1», «gene», «genes», «pharmacogenetics», «pharmacogenomics», «ethnic group».Results. Generalization of information allowed to identify obscure genes that need to be investigated in pharmacogenetic studies. This information can be used for the development of dosing algorithms and the priority choice of drugs, considering the results of pharmacogenetic testing and planning future research.Conclusion. The results of the literature review indicate the importance of studying the most clinically valid and clinically useful pharmacogenetic markers (CYP2C19, CYP2C9, VKORC1, SLCO1B1) among various ethnic groups in the Russian Federation. With the accumulation of evidence of clinical validity and clinical utility of other pharmacogenetic markers (CES1, CYP2D6*4, etc.), the problem of interethnic differences in the carriage of clinically significant polymorphisms of these genes identified in previous studies in the Russian Federation increasingly requires attention. The most promising for the introduction into the clinical practice in the Russian Federation in the near future are polymorphic markers of the CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes.

1 July 2019 in Pharmacogenomics
Verified
Journal Article
Closed access
KMKarin B Mirzaev
Karin B Mirzaev
DFDenis Fedorinov
Denis Fedorinov
DIDmitry V Ivashchenko
Dmitry V Ivashchenko
DSDmitry Sychev
Dmitry Sychev
This systematic review reflects the results of pharmacogenetic studies in the Russian Federation aimed at studying the genes involved in the drug biotransformation system. The works of Russian researchers found by us are mostly devoted to microsomal liver oxidation enzymes (metabolism) and membrane transporter systems (absorption and excretion). This review presents population-ethnic and associative clinical studies on the genes of the CYP450 system, noncytochrome oxidation enzymes (SULT1A1, CES1), membrane transporter system genes (ABCB1, SLCO1B1) and warfarin biotransformation enzymes (VKORC1, GGCX). The information is structured in the form of 11 tables, divided by regions of the Russian Federation.

1 February 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
TBTatiana Sergeevna Boldyreva
Tatiana Sergeevna Boldyreva
AZAlina Yurievna Zatsepina
Alina Yurievna Zatsepina
DFDenis Fedorinov
Denis Fedorinov
Vladimir K. LyadovVladimir K. Lyadov
Vladimir K. Lyadov

16 October 2018 in Drug Metabolism and Personalized Therapy
Verified
Journal Article
Closed access
PDF file
DFDenis Fedorinov
Denis Fedorinov
KMKarin B. Mirzaev
Karin B. Mirzaev
VMVioletta R. Mustafina
Violetta R. Mustafina
DSDmitry Sychev
Dmitry Sychev
NMNadezda R. Maximova
Nadezda R. Maximova
ZRZoya A. Rudykh
Zoya A. Rudykh
Background: The aim of this study was to determine carrier frequencies of the polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease (CHD) patients in Russian and Yakut ethnic groups. The association between the administration of higher doses of bisoprolol and metoprolol and the carriage of these polymorphic markers related to the decreased function of the haplotype of CYP2D6 was also studied.Methods: The study included 201 CHD patients (aged 66±8.7 years) receiving metoprolol in titrated dose (12.5–150 mg), bisoprolol (2.5–10 mg) or atenolol (50 mg). Ninety-three patients were Russian (30 men and 63 women), and 108 patients were Yakut (54 men and 54 women).Results: In genotyping CHD patients in the Russian and Yakut ethnic groups, there was no significant difference in the prevalence rate of the polymorphic markers G1846A (10.8 vs. 10.2; p=0.871) and C100T (16.1 vs. 16.2; p=1). In patients carrying the polymorphic marker G1846A, the dose of bisoprolol was established to be lower than that in the control group (p=0.0289).Conclusions: The carriage frequency of polymorphic markers, which theoretically should differ between Russians and Yakuts as representatives of two different races, in practice turned out to be the same.

3 July 2018 in Drug Metabolism and Personalized Therapy
Verified
Journal Article
Closed access
PDF file
KMKarin B. Mirzaev
Karin B. Mirzaev
EREric Rytkin
Eric Rytkin
KRKristina A. Ryzhikova
Kristina A. Ryzhikova
EGElena A. Grishina
Elena A. Grishina
ZSZhannet A. Sozaeva
Zhannet A. Sozaeva
DSDmitry Sychev
Dmitry Sychev
Background: The aim was to study seven polymorphic markers of genes encoding proteins involved in the absorption, metabolism and pharmacokinetics of clopidogrel among patients with an acute coronary syndrome (ACS), who have undergone percutaneous coronary intervention (PCI). Methods: Eighty-one ACS and PCI patients older than 18 years and treated with dual antiplatelet therapy were enrolled in the study. Platelet function testing and ABCB1 , CYP2C19 , CYP3A5 and CYP4F2 genotyping were performed. The predictive role of categorical variables, such as genotypes (carriers and non-carriers of polymorphism), on platelet reactivity (platelet reactivity units [PRU] platelet inhibition [PI]) was assessed by logistic regression (for categorical outcomes) and linear regression (for continuous outcomes) analysis. A p-value<0.05 was considered significant. The allele frequencies were estimated by gene counting, and Hardy-Weinberg equilibrium was tested using the chi-square test. Results: Regarding clopidogrel response, 62 patients (76.5%) were clopidogrel responders and 19 were non-responders (23.5%). Mean PRU value and the percentage of platelet inhibition were 170.0±50.9 PRU and 28.6±19.9%, respectively. The effects of the CYP2C19*2 polymorphisms on PRU (166.0±50.8 vs. 190.7±48.2, p<0.038) and PI (30.6±20.0 vs. 18.1±16.3, p<0.013) were observed, and the rates of high platelet reactivity (HPR) were lower in CYP2C19*1/*1 than those in CYP2C19*1/*2+CYP2C19*2/*2 (16.2% vs. 53.8% p<0.0067). In comparison, no significant difference in PRU value and PI was observed at 0.05). Based on the logistic regression analysis, CYP2C19*2 (OR: 4.365, CI: 1.25–17.67, p=0.022) was an independent predictor of HPR at <5 days, as was the stent diameter (OR: 0.219, CI: 0.002–0.229, p=0.049). The remaining polymorphisms had no influence. Conclusions: The reactivity of the on-clopidogrel platelet in the early phase of ACS is influenced primarily by the CYP2C19 polymorphisms. We believe that the findings of the present study could supply additional evidence regarding the clinical appropriateness of the CYP2C19 genetic testing for designing suitable antiplatelet therapy in the early phase of ACS.

16 June 2020 in Pharmacogenomics
Verified
Journal Article
Closed access
KMKarin Mirzaev
Karin Mirzaev
SASherzod Abdullaev
Sherzod Abdullaev
KAKristina Akmalova
Kristina Akmalova
JSJeannette Sozaeva
Jeannette Sozaeva
EGElena Grishina
Elena Grishina
DSDmitry Sychev
Dmitry Sychev
Background: The aim of this study was to determine the prevalence of CYP2C9, VKORC1, CYP2C19, ABCB1, CYP2D6 and SLCO1B1 genes polymorphisms among residents of the Volga region (Chuvash and Mari) an...